Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 4/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5369342 | 0.85 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3CCR3TACR1 | |
| SCHEMBL5356990 | 0.83 | DRD2 (0.53) | SLC6A4SLC6A2SLC6A3CCR3TACR1 | |
| SCHEMBL5361885 | 0.82 | SLC6A4 (0.62) | SLC6A4SLC6A2SLC6A3CCR3 | |
| SCHEMBL14359682 | 0.79 | DPP4 (0.52) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL27982226 | 0.79 | ALDH1A1 (0.44) | SLC6A4SLC6A2SLC6A3CCR3TMEM97 | |
| SCHEMBL16565196 | 0.77 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL16521003 | 0.76 | SLC6A4 (0.65) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL14417149 | 0.76 | CCR3 (0.39) | SLC6A4SLC6A2SLC6A3CCR3SIGMAR1 | |
| SCHEMBL21078004 | 0.76 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3CCR3TACR1 | |
| SCHEMBL5369345 | 0.75 | SLC6A2 (0.36) | SLC6A4SLC6A2SLC6A3CCR3TMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217823-B2 | 4,4-Disubstituted piperidines, and methods of use thereof | SEPRACOR INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HOEMANN MICHAEL Z (US) | 2004-07-22 | — | — | US | disclosed |
| US-6656953-B2 | Ligands for receptors such as dopamine, serotonin, or norepinephrine transporters; broad uses claimed, such as pain reliever and antidepressant | SEPRACOR INC. | 2003-12-02 | — | — | US | disclosed |
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | SEPRACOR INC. | 2002-11-28 | — | — | US | disclosed |
| WO-2002046156-A2 | 4,4-DISUBSTITUTED PIPERIDINES FOR USE AS DOPAMINE, SEROTONIN AND NOREPINEPHRINE LIGANDS | SEPRACOR, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177607-A1 | 4,4-Disubstitued piperidines, and methods of use thereof | HTR2C, HTR5A, OPRL1 | SLC6A4 10/4885SLC6A2 14/4885SLC6A3 4/4885 |
| US-20070225331-A1 | 4,4-Disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | SLC6A4 11/4885SLC6A2 14/4885SLC6A3 5/4885 |
| US-20040142974-A1 | 4,4-disubstituted piperidines, and methods of use thereof | HTR5A, HTR2C, OPRL1 | SLC6A4 11/4885SLC6A2 14/4885SLC6A3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.